{
    "clinical_study": {
        "@rank": "15058", 
        "acronym": "REMIND", 
        "arm_group": [
            {
                "arm_group_label": "1", 
                "arm_group_type": "Experimental", 
                "description": "Dotarem\u00ae-enhanced MRI, then Gadovist\u00ae/Gadavist\u00ae-enhanced MRI"
            }, 
            {
                "arm_group_label": "2", 
                "arm_group_type": "Experimental", 
                "description": "Gadovist\u00ae/Gadavist\u00ae-enhanced MRI then Dotarem\u00ae enhanced MRI"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to demonstrate non-inferiority of Dotarem\u00ae-enhanced MRI as\n      compared to Gadovist\u00ae/ Gadavist\u00ae-enhanced MRI in the diagnosis of brain tumors in terms of\n      overall lesion visualization and characterization (off-site assessment).\n\n      270 patients will be randomized between 2 arms defining the sequence of administration of\n      the contrast agents at the dose of 0.1mmol/kg, with a minimum of 48 hours and a maximum of\n      14 days in between.\n\n      Each patient will, therefore, receive two MRI during his/her participation in the study.\n\n      The two arms consist in :\n\n        -  Dotarem\u00ae in the first MRI, then Gadovist\u00ae/Gadavist\u00ae in the second MRI.\n\n        -  Gadovist\u00ae/Gadavist\u00ae in the first MRI, then Dotarem\u00ae in the second MRI.\n\n      Contrast-enhanced MRIs will be performed on 1.5 or 3 Tesla systems.\n\n      MRI examinations will be evaluated centrally by blinded independent readers for the main\n      evaluation criterion."
        }, 
        "brief_title": "Efficacy Evaluation of Dotarem\u00ae-Enhanced MRI Compared to Gadovist\u00ae/Gadavist\u00ae-Enhanced MRI in the Diagnosis of Brain Tumors", 
        "completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Primary Brain Tumor", 
        "condition_browse": {
            "mesh_term": "Brain Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Female or male adult patient (patient having reached legal majority age)\n\n          -  Patient with known or highly suspected primary intracranial tumors (intra-axial or\n             extra-axial) detected by previous CT or MRI examination who are scheduled to undergo\n             a routine contrast-enhanced MRI\n\n          -  Female patient must have effective contraception throughout the study and must have a\n             negative urine pregnancy test at inclusion, or be surgically sterilized, or\n             post-menopausal (minimum 12 months of amenorrhea)\n\n          -  Patient having provided his/her written informed consent to participate in the trial\n             prior to any study-related procedure being conducted\n\n          -  Patient with national health insurance (according to local regulatory requirements)\n\n        Exclusion Criteria:\n\n          -  Patient with rapidly evolving brain tumor that could change in appearance between the\n             time of the two study MRI examinations.\n\n          -  Patient undergoing current or recent treatment within past 6 weeks or scheduled for\n             any treatment that could results in changes of lesion appearance between the two\n             study examinations. This would include, but not restricted to, the following: current\n             or recent radiation therapy, surgery, starting or recent chemotherapy.\n\n          -  Patient with a contraindication to MRI (e.g., pacemaker, aneurysm clip, severe\n             claustrophobia, infusion pumps, cochlear implants metallic or others according to the\n             imaging site standard practice)\n\n          -  Patient with known severely impaired renal function (defined as eGFR MDRD< 30\n             ml/min/1.73m2)\n\n          -  Patient with known Class III/IV congestive heart failure according to the New York\n             Heart Association classification\n\n          -  Patient with known severe adverse drug reaction or contraindication to\n             Gadolinium-Based Contrast Agent\n\n          -  Patient having received any contrast agent within 48 hours prior to first study\n             contrast agent injection scheduled for the study and patient expected to receive any\n             other contrast agent within 24 hours of the last study contrast agent injection\n\n          -  Patient presenting with any condition which, based on the investigator's clinical\n             judgment, would prevent the patient from completing all trial assessments and visits\n\n          -  Patient under guardianship and/or unable or unwilling to cooperate with the\n             requirements of this trial\n\n          -  Pregnant or breast feeding female patient\n\n          -  Patient already included in this trial\n\n          -  Patient included in another clinical trial involving an IMP within 30 days before the\n             first investigational contrast agent injection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "270", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 10, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02034708", 
            "org_study_id": "DGD-44-058"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "1", 
                    "2"
                ], 
                "description": "Dotarem\u00ae 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus. The study dose will be injected, using an automatic injector, in an intravenous (IV) bolus at a rate of 1 mL/sec, and followed by a saline flushing (20-30mL at 2mL/sec).", 
                "intervention_name": "Dotarem\u00ae", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "1", 
                    "2"
                ], 
                "description": "Gadovist\u00ae/Gadavist\u00ae, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.The study dose will be injected, using an automatic injector, in an intravenous (IV) bolus at a rate of exactly 0.5 mL/sec, and followed by a saline flushing (20-30mL at 2mL/sec).", 
                "intervention_name": "Gadovist\u00ae/Gadavist\u00ae", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Primary brain tumor", 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Farmington Hills", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "Quest Research Institute"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cali", 
                        "country": "Colombia"
                    }, 
                    "name": "Centro Medico Imbanaco"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monterrey", 
                        "country": "Mexico", 
                        "state": "Nuevo Le\u00f3n"
                    }, 
                    "name": "Winsett Rethman S.A. de C.V."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Monterrey", 
                        "country": "Mexico"
                    }, 
                    "name": "Centro Regiomontano de Investigacion S.C."
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tlanepantla", 
                        "country": "Mexico"
                    }, 
                    "name": "Clinical Research Institute S.C."
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Colombia", 
                "Mexico"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Intra-individual Cross-over Efficacy Evaluation of Dotarem\u00ae-Enhanced MRI Compared to Gadovist\u00ae/ Gadavist\u00ae-Enhanced MRI in the Diagnosis of Brain Tumors", 
        "overall_contact": {
            "email": "camille.pitrou@guerbet-group.com", 
            "last_name": "Camille Pitrou"
        }, 
        "overall_contact_backup": {
            "email": "corinne.dubourdieu@guerbet-group.com", 
            "last_name": "Corinne Dubourdieu"
        }, 
        "overall_official": {
            "affiliation": "University of Washington Medical Center, Seattle, USA", 
            "last_name": "Kenneth Maravilla, MD", 
            "role": "Study Chair"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Colombia: INVIMA Instituto Nacional de Vigilancia de Medicamentos y Alimentos", 
                "Mexico: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "October 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Overall lesion visualization and characterization, based on assessment of the primary or largest lesion if there is more than one lesion present, assessed by 3 independent off-site readers, based on a 4-point scale:\n0. Poor: does not allow adequate visualization and characterization of the lesion; 1. Fair: allows partial visualization and characterization of the lesion ; 2. Good: allows adequate visualization and characterization of the lesion; 3. Excellent: allows excellent visualization and characterization of the lesion.", 
            "measure": "Overall lesion visualization and characterization", 
            "safety_issue": "No", 
            "time_frame": "Up to 15 days after randomization"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02034708"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Guerbet", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Guerbet", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}